Chimeric Therapeutics Ltd (ASX:CHM), a clinical-stage cell therapy company, has had two CHM 1101 (CLTX CAR T) abstract presentations accepted for the 26th annual Society for Neuro-Oncology (SNO) scientific meeting to be held November 18-21, 2021.
Clinical evaluation of the initial dose cohort in the phase 1 clinical trials for CHM 1101 (CLTX CAR T) will be presented on Friday, November 19, within abstract CTIM-29.
This presentation will provide new information on the safety, efficacy and bioactivity of CHM 1101 in patients treated at the initial low dose level of 44 X 106 cells with intratumoral administration in the ongoing phase 1 clinical trial.
Abstract EXTH-10, to also be presented on Friday, November 19, will provide further insight into the mechanism by which CHM 1101 (CLTX CAR T) recognises glioblastoma tumour cells.
Premier neurooncology meeting
The inclusion of these abstracts in the premier global neuro-oncology meeting recognises the importance of the development of CHM 1101 (CLTX CAR T) to the field of neuro-oncology drug development.
Chimeric developed CHM 1101 as a novel and promising chimeric antigen receptor (CAR) T cell therapy for the treatment of patients with Glioblastoma (GBM). Developed by scientists at the City of Hope Medical Centre in California, it is currently being studied in a phase 1 clinical trial.
Glioblastoma is the most common and aggressive malignant primary brain tumor in adults. Current treatment options involve surgery followed by chemotherapy or more frequently radiotherapy, but patient survival remains at just over one year.
CAR T cells are collected from patients' Cytotoxic T lymphocytes – a type of immune cell that has the capacity to directly kill other cells – and genetically modified to express a chimeric antigen receptor (CAR) specific for an identified tumour antigen. These CAR T cells are then readministered to the patient to identify and eliminate cancer cells.
Read: Chimeric Therapeutics granted European patent for cancer-fighting asset CHM 1101
Critical for clinical development
“These data are critical to advancing our clinical development program. At the low dose level that patients in this cohort received, we are focused on being able to establish safety and bioactivity in patients,” Chimeric’s CEO and managing director Jennifer Chow said.
“Once we are able to further characterise the safety and bioactivity of CHM 1101, we will be able to move forward to focus on our exploration of efficacy at the higher dose levels in the trial with dual routes of administration.”
Chimeric's pipeline was recently expanded with the additional licensing of CHM 2101, a novel third-generation CDH17 CAR T invented at the University of Pennsylvania.
The cell therapy is currently in preclinical development with a phase 1 clinical trial planned for 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.
Novel findings to be presented in Abstract EXTH-10 continue to advance Chimeric’s understanding of the precise composition and localization of the cell surface complex recognised by CLTX CAR T.
Presentation details
The Society for Neuro-Oncology 26th annual scientific meeting from November 18-21, 2021, can be accessed by registering here.
Chimeric Therapeutics’ abstract presentation details are as follows:
Abstract #: CTIM-29
Abstract Title: Clinical evaluation of chlorotoxin-directed CAR T cells for patients with recurrent glioblastoma
Presentation Date: Friday, November 19, 2021
Abstract #: EXTH-10
Abstract Title: Exploration of a novel toxin-incorporating CAR T cell: how does chlorotoxin recognise glioblastoma cells?
Presentation Date: Friday, November 19, 2021